Madrigal Pharmaceuticals (MDGL) Cash from Operations (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 17 years of Cash from Operations data on file, last reported at 167435000.0 in Q1 2026.

• On a quarterly basis, Cash from Operations fell 88.36% year-over-year to 167435000.0 in Q1 2026; TTM through Mar 2026 was 268097000.0, a 32.18% increase from a year earlier, with the FY2025 full-year figure at 189553000.0, up 58.39% from the prior year.
• Cash from Operations for Q1 2026 stood at 167435000.0, down from 133460000.0 in the prior quarter.
• Over the last five years, Cash from Operations for MDGL reached as high as 79850000.0 in Q3 2025 and fell as low as 167435000.0 in Q1 2026.
• Historically, Cash from Operations has averaged 80096882.35 across 5 years, with a median of 79933000.0 in 2023.
• Across the five-year window, Cash from Operations surged 219.21% in 2025 and tumbled 88.36% in 2026, its largest moves.
• Year by year, Cash from Operations stood at 58515000.0 in 2022, then sank by 36.6% to 79933000.0 in 2023, then sank by 30.72% to 104486000.0 in 2024, then retreated by 27.73% to 133460000.0 in 2025, then decreased by 25.46% to 167435000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were 167435000.0 in Q1 2026, 133460000.0 in Q4 2025, and 79850000.0 in Q3 2025.